Physician profile

Jing Li

Radiation Oncology · Houston, TX

NPI 1316239502

$17,665.80

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$9,922.50
Travel and Lodging$968.64
Food and Beverage$393.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Servier Pharmaceuticals LLC $11,061.06 2024
Novocure INC. $5,026.21 2019-2020
Monteris Medical Corporation $1,200.00 2020
Elekta, INC. $188.33 2023-2024 Elekta Medical Linear Accelerator
Brainlab, INC. $129.65 2022-2023 Image Guided Surgical Device
Varian Medical Systems, INC. $60.55 2020

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jing Li

$17,665.80

in general payments reported 2019-2025

Years
2019-2024
Top company
Servier Pharmaceuticals LLC

https://glasscript.com/doctor/150762/jing-li

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.